FOXO TECHNOLOGIES INC.

FOXO Technologies Inc. (Nasdaq: FOXO) is an insurtech company focused on leveraging epigenetic biomarker science to modernize life insurance underwriting and product development. The company went public through a business combination with CF Acquisition Corp. VIII, a blank-check vehicle sponsored by Cantor Fitzgerald, which completed its IPO in 2021. The June 2022 Form 8-K filing, accession number 0001213900-22-031560, relates to disclosures made during the de-SPAC transaction process; the merger was ultimately consummated in late 2022, bringing FOXO into the public markets under its current ticker. The company operates at the intersection of life sciences and financial services. Visit SpacDesk and sign up for full filing data, transaction timelines, and sponsor analytics on FOXO and thousands of other SPAC deals.